Biolase IncFind Ratings Reports
BIOLASE INC's gross profit margin for the first quarter of its fiscal year 2017 has increased when compared to the same period a year ago. Even though sales decreased, the net income has increased. BIOLASE INC has weak liquidity. Currently, the Quick Ratio is 0.76 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
During the same period, stockholders' equity ("net worth") has decreased by 14.94% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY17||Q1 FY16|
|Net Sales ($mil)||10.87||11.01|
|Net Income ($mil)||-4.11||-4.27|
|Balance Sheet||Q1 FY17||Q1 FY16|
|Cash & Equiv. ($mil)||3.83||6.83|
|Total Assets ($mil)||37.04||38.42|
|Total Debt ($mil)||0.12||0.16|
|Profitability||Q1 FY17||Q1 FY16|
|Gross Profit Margin||39.02||35.02|
|Return on Assets||-41.07||-49.73|
|Return on Equity||-94.72||-88.48|
|Debt||Q1 FY17||Q1 FY16|
|Share Data||Q1 FY17||Q1 FY16|
|Shares outstanding (mil)||67.66||58.26|
|Div / share||0.0||0.0|
|Book value / share||0.27||0.37|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||95083.0||65470.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 2.21 indicates a discount versus the S&P 500 average of 3.02 and a significant discount versus the industry average of 4.79. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount. After reviewing these and other key valuation criteria, BIOLASE INC proves to trade at a discount to investment alternatives within the industry.
|BIOL NM||Peers 47.77||BIOL NM||Peers 37.41|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
BIOL's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
BIOL's P/CF is negative making the measure meaningless.
|BIOL NM||Peers 32.84||BIOL NA||Peers 1.00|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
BIOL's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|BIOL 2.21||Peers 4.79||BIOL 12.50||Peers 34.43|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
BIOL is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, BIOL is expected to significantly trail its peers on the basis of its earnings growth rate.
|BIOL 0.79||Peers 5.07||BIOL 6.25||Peers 11.44|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
BIOL is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
BIOL significantly trails its peers on the basis of sales growth